# Study on B7-H3 Targeted Affibody Radioligand Probes for PET Imaging of Solid Tumors

> **NCT06454955** · EARLY_PHASE1 · RECRUITING · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 50 (estimated)

## Conditions studied

- B7H3
- CD276 Affibody
- PET/CT Imaing

## Interventions

- **DRUG:** [68Ga] B7H3 Affibody-BCH

## Key facts

- **NCT ID:** NCT06454955
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-01
- **Primary completion:** 2024-11-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06454955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06454955, "Study on B7-H3 Targeted Affibody Radioligand Probes for PET Imaging of Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06454955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*